Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05821933` - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT03269162` - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection	Phase 3
Recruiting	`NCT05002270` - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation	Phase 1/Phase 2
Recruiting	`NCT06315686` - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA	Phase 2
Active, not recruiting	`NCT05059522` - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	Phase 3
Recruiting	`NCT05466149` - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion	Phase 2
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Completed	`NCT03609918` - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting	`NCT06043817` - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT05078931` - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients	Phase 2
Not yet recruiting	`NCT05547737` - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting	`NCT05909137` - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn	`NCT05959473` - EGFR_IUO 3.20 Clinical Study Protocol	N/A
Not yet recruiting	`NCT05005468` - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.	Phase 2
Recruiting	`NCT01690390` - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease	Phase 2
Completed	`NCT01852578` - Cabazitaxel in Relapsed and Metastatic NSCLC	Phase 2
Active, not recruiting	`NCT01460472` - Immunotherapy With Racotumomab in Advanced Lung Cancer	Phase 3
Completed	`NCT00866970` - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia	Phase 2
Completed	`NCT00702975` - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy	Phase 2

NCT number	NCT03794544
Study type	Interventional
Source	MedImmune LLC
Contact
Status	Completed
Phase	Phase 2
Start date	March 8, 2019
Completion date	January 13, 2021

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms